Durable benefits previously reported for the MADRS depression scale are supported by the patient-reported outcome of PGI-S and new MADRS responder analyses that underscore benefit at week 10 with a 50% higher rate of remission of depression SYDNEY , Aug. 26, 2024 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "the Company") announces that on-going analysis of the XanaCIDD phase 2a depression trial data found a consistent benefit of Xanamem ® treatment on symptoms of depression in a variety of different endpoints. The consistent benefits observed support the conclusion that a 10 mg Xanamem dose is active in controlling brain cortisol and has clinically significant anti-depressant activity.
Highlights of the updated results are: MADRS [1] depression score improvement confirmed (p < 0.05) and positive effects were observed in five of six pre-specified subgroups, indicating broad effect in the population studied Analysis of further data from a second, well-validated endpoint for clinical function in depression, called the Patient Global Impression of Severity (PGI-S) [2] , reveals consistent Xanamem benefits that corroborate MADRS observations New MADRS responder analyses underscore MADRS benefit at Week 10 with a 50% higher rate of remission of depression [3] Maximal benefits on depression for all endpoints at Week 10, four weeks after the end of treatment, indicate a durable therapeutic effect resulting from controlling brain cortisol Xanamem's durable therapeutic effect.